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Cancer patients commonly experience a number of symptoms of disease progression
and the side-effects of radiation therapy and adjuvant chemotherapy, which adversely
impact on their quality of life (QOL). Fatigue is one of the most common and debilitating
symptom reported by cancer patients and can affect QOL more than pain. Several recent
studies have indicated that intravenous (IV) vitamin C alleviates a number of cancer- and
chemotherapy-related symptoms, such as fatigue, insomnia, loss of appetite, nausea, and
pain. Improvements in physical, role, cognitive, emotional, and social functioning, as well as
an improvement in overall health, were also observed. In this mini review, we briefly cover
the methods commonly used to assess health-related QOL in cancer patients, and describe
the few recent studies examining the effects of IV vitamin C on cancer- and chemotherapy-
related QOL. We discuss potential mechanisms that might explain an improvement in QOL
and also considerations for future studies.
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INTRODUCTION
High-dose intravenous (IV) vitamin C has been administered by
physicians for many decades as a complementary and alternative
therapy for cancer patients (1). Although the use of IV vitamin C is
relatively common, there is still controversy as to its efficacy in the
treatment of cancer (2). Much of the controversy can be attributed
to the lack of an agreed mechanism of action, and numerous issues
around study design, including a lack of understanding of vitamin
C pharmacokinetics (3). Vitamin C administered intravenously
bypasses the regulated intestinal uptake mechanism and results
in significantly higher plasma concentrations than are obtained
through oral intake (4). It is proposed that at these high-doses
vitamin C acts as a pro-drug via metal ion-dependent generation
of cytotoxic hydrogen peroxide (3), however, other potential anti-
cancer mechanisms, such as regulation of epigenetic marks and
transcription factors, are also possible (5).
Recently, evidence has been accumulating which indicates that
IV vitamin C may improve the quality of life (QOL) of cancer
patients, both in the presence and absence of adjuvant chemo-
and radiotherapy (6–9). Two early studies of high-dose vita-
min C in patients with advanced cancer indicated that many of
the patients experienced some subjective improvement in QOL,
including reduced pain and the need for analgesics (10, 11). The
authors stated that “any agent which can make, or even appear
to make, the burden of terminal cancer more tolerable, deserves
further study.” Health-related QOL encompasses the general well-
being of an individual and comprises both objective and subjective
measures, the latter of which can be difficult to measure and
quantify. In this mini review, we briefly cover the methods com-
monly used to assess health-related QOL in cancer patients, and
describe the few recent studies examining the effects of IV vitamin
C on cancer- and chemotherapy-related QOL. We discuss potential
mechanisms that might explain an improvement in QOL and also
considerations for future studies.
QUALITY OF LIFE AND FATIGUE MEASURES
Numerous instruments exist that can be used to assess health-
related QOL in cancer patients (12). These include general mea-
sures such as the short form 36 (SF-36) and the EuroQoL 5
dimensions (EQ-5D), as well as specific measures such as the
functional assessment of cancer therapy-general (FACT-G) and
the European organization for research and treatment of cancer
quality of life questionnaire (EORTC QLQ-C30) (13). The UK
national institute for health and clinical practice (NICE) recom-
mends generic measures such as the EQ-5D in order to compare
different disease conditions, however, the EQ-5D has been criti-
cized for its lack of sensitivity with cancer patients (14), and the
SF-36 also does not appear to perform as well as the EORTC QLQ-
C30 (15). The FACT-G and EORTC QLQ-C30 perform equally
well (13) and three of the four studies assessing the effect of IV vit-
amin C on cancer-related QOL have used the EORTC QLQ-C30 (6,
8, 9). The EORTC QLQ-C30 is a reliable and valid QOL question-
naire comprising 30 core items (16). Multi-item scales include five
functional scales (physical, role, cognitive, emotional, and social),
three symptom scales (fatigue, pain, and nausea/vomiting), and a
global health and QOL scale. Additional single item scales include
symptoms commonly reported by cancer patients (e.g., dyspnea,
appetite loss, sleep disturbance, constipation, and diarrhea) as well
as the financial impact of the disease and treatment. The measures
range in score from 0 to 100, with a difference of 4–10 points
representing a small change, and a difference of 10–20 points
representing a medium change in QOL (17).
Fatigue is one of the most common and debilitating symptom
reported by cancer patients and can affect QOL more than pain
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(18). Numerous measures of fatigue have been developed, includ-
ing the fatigue severity scale (FSS), fatigue impact scale (FIS), and
the brief fatigue inventory (BFI) (19). However, fatigue is not one-
dimensional, i.e., it has physical, emotional, and mental aspects,
therefore, multidimensional measures offer more comprehensive
information. These measures include the fatigue symptom inven-
tory (FSI), multidimensional assessment of fatigue (MAF), and
multidimensional fatigue symptom inventory (MFSI) (19). Some
instruments have been validated for the measurement of cancer-
related fatigue and are therefore preferred, e.g., BFI and MFSI
(20). The use of standardized instruments facilitates cross study
comparisons. We have used the MFSI-SF (21) to assess the effects
of IV vitamin C on the multidimensional aspects of cancer- and
chemotherapy-related fatigue (22, 23).
CHEMOTHERAPY-RELATED QUALITY OF LIFE
Patients undergoing chemotherapy commonly experience fatigue,
with more than 75% of patients reporting feelings of debili-
tating tiredness or loss of energy (18). Fatigue has a constant
presence following chemotherapy, increases incrementally with
consecutive cycles of chemotherapy (24), and may persist for
years after treatment completion (25). Although cancer-related
pain can be managed with opioids (26), no effective therapy
for fatigue has yet been identified. The efficacy of IV vitamin
C administration on the QOL of breast cancer patients during
chemo-/radiotherapy and aftercare was investigated in a retro-
spective cohort study (7). A total of 53 patients were treated with
7.5 g vitamin C once a week for a minimum of 4 weeks (not on
the days of chemo-/radiotherapy) and compared with 72 con-
trols. Intensity of complaints was measured on a scale of 0= no
complaints, 1=mild complaints, and 2= severe complaints. Sig-
nificantly decreased fatigue, depression, sleep disorders, and loss
of appetite were observed in the treatment group compared with
the control group during chemo-/radiotherapy (Table 1). During
the after-care phase, a significant decrease in fatigue, sleep disor-
ders, dizziness, nausea, and loss of appetite was observed in the
treatment group.
A subsequent prospective intervention study investigated the
health-related QOL of 60 patients with advanced cancer, about half
of whom were undergoing chemotherapy during the study period
(9). IV vitamin C (25–100 g/session) was administered twice a
week and EORTC QLQ-C30 questionnaires were completed before
and following 2 and 4 weeks of vitamin C intervention. A statis-
tically significant decrease in fatigue, insomnia, and constipation
was observed following 2 weeks, and a reduction in pain follow-
ing 4 weeks of intervention (Table 1). Significant improvements
in physical, role, emotional, and social function were observed
following 2 weeks and an improvement in cognitive function-
ing following 4 weeks. Overall, the patients’ global health status
improved from a score of 45 to a score of 61 after 4 weeks of IV
vitamin C.
We carried out a case study of a 45-year-old female diag-
nosed with breast cancer (22). Lethargy was a major symptom of
chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel).
To investigate the effects of pharmacologic vitamin C on QOL
and fatigue due to chemotherapy, IV vitamin C (50 g/session) was
initiated twice weekly, 2 days either side of each chemotherapy
session. QOL (EORTC QLQ-C30) and fatigue (MFSI-SF) ques-
tionnaires were undertaken before and after 4 weeks of vitamin
C intervention (16, 21). The QOL questionnaire showed dra-
matic decreases in fatigue, pain, appetite loss, nausea/vomiting,
and insomnia following vitamin C administration (Table 1).
Increases in physical, emotional, cognitive, and social functioning
were also observed, as well as a doubling of the patient’s “global
health status.”The multidimensional fatigue symptomology ques-
tionnaire showed decreases in general, physical, emotional, and
mental fatigue, as well as increased vigor, following vitamin C
administration.
Although not addressing QOL directly, a recent translational
study showed reduced chemotherapy-related toxicity when high-
dose IV vitamin C was administered in conjunction with carbo-
platin and paclitaxel (27). Twenty-five patients with stage III–IV
ovarian cancer were randomized to receive either chemother-
apy alone (for 6 months) or chemotherapy plus IV vitamin C
(75–100 g two times per week for 12 months). Adverse events
were evaluated and grade 1 and 2 toxicities were found to
be significantly decreased in the group receiving IV vitamin C
(Table 1). Decreased toxicities were observed in almost all the
evaluated categories, e.g., neurological, bone marrow, hepatobil-
iary/pancreatic, renal/genitourinary, infection, pulmonary, gas-
trointestinal, and dermatological. Interestingly, the decreased tox-
icity did not adversely affect survival of the patients, suggest-
ing that IV vitamin C is a potentially useful adjuvant to some
chemotherapeutic agents. In support of a role for vitamin C in
decreasing chemotherapy-related toxicity, a phase I clinical study
of pharmacologic vitamin C in combination with gemcitabine (for
the control of pancreatic cancer) reported decreased plasma F2-
isoprostanes, a well validated biomarker for endogenous oxidative
stress, following administration of IV vitamin C (28).
PALLIATIVE CARE OF END-STAGE PATIENTS
In patients with advanced cancer, where a cure is unlikely, QOL
becomes an important and highly valued consideration for both
the patients and their families. Yeom et al. (6) carried out a
prospective study of 39 terminal cancer patients who were not
undergoing adjuvant chemo-/radiotherapy. The patients were
administered IV vitamin C (10 g twice over 3 days) followed by
oral vitamin C intake (4 g/day for 1 week). The EORTC QLQ-C30
was used to assess QOL before and after vitamin C administra-
tion. The patients reported significantly lower scores for fatigue,
pain, nausea/vomiting, and appetite loss following administration
of vitamin C (Table 1). The patients also reported significantly
higher scores for physical, role, emotional, and cognitive function,
as well as an overall improvement in their global health scale (from
a score of 36 to a score of 55) following vitamin C administration.
A recent phase I clinical trial designed to test the safety, toler-
ability, and pharmacokinetics of IV vitamin C in patients with
advanced cancer also measured health-related QOL using the
EORTC QLQ-C30 (8). Patients with refractory advanced solid
tumors (n= 17) were treated with IV vitamin C at 0.8–3 g/kg
body weight for 1–4 weeks. The QOL assessment gave variable data
depending on the week and sample size, but overall there appeared
to be an improvement in most functioning and symptom scales
for weeks 2 and 4 (Table 1).
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Table 1 | Intravenous vitamin C and cancer-/chemotherapy-related quality of life.
Study type Patients Intervention Other therapies Measures Outcomes
PROSPECTIVE
Ma et al. (27) 25 Ovarian cancer (stage
III–IV)
13 Chemo+ vitC group
12 Chemo group
IV vitamin C
75–100 g
2× /week
12 months
± Chemotherapy
(paclitaxel, carboplatin)
6 months
Adverse
events/toxicity
↓ Grade 1 and 2 toxicities (neurological,
bone marrow, hepatobiliary/pancreatic,
renal/genitourinary, pulmonary,
infection, gastrointestinal, and
dermatological)
Stephenson et al. (8) 17 Refractory advanced solid
tumors (stage III–IV; colon,
pancreas, breast, etc.)
IV vitamin C
0.8–3 g/kg
4× /week
1–4 weeks
None EORTC QLQ-C30a ↓ Fatigue
↓ Pain
↓ Nausea/vomiting
↓ Insomnia
↓ Appetite loss
↑ Global health
↑ Physical, role, emotional,
cognitive, and social
functioning
Takahashi et al. (9) 60 Advanced cancer (lung,
breast, stomach, colon, etc)
IV vitamin C
25–100 g
2× /week
4 weeks
± Chemotherapy EORTC QLQ-C30 ↓ Fatigue
↓ Pain
↓ Insomnia
↓ Constipation
↑ Global health
↑ Physical, role, emotional,
cognitive, and social
functioning
Yeom et al. (6) 39 Terminal cancer (stomach,
colorectal, lung, breast,
biliary, etc)
IV vitamin C
10 g 2× /week
4 g oral daily
1 week
None EORTC QLQ-C30 ↓ Fatigue
↓ Pain
↓ Nausea/vomiting
↓ Insomnia
↓ Appetite loss
↑ Global health
↑ Physical, role, emotional,
cognitive, and social
functioning
CASE STUDIES
Carr et al. (22) 1 Breast cancer IV vitamin C
50 g 2× /week
4 weeks
Chemotherapy
(doxorubicin,
cyclophosphamide,
paclitaxel)
EORTC QLQ-C30 ↓ Fatigue
↓ Pain
↓ Nausea/vomiting
↓ Insomnia
↓ Appetite loss
↑ Global health
↑ Physical, emotional,
cognitive, and social
functioning
MFSIb ↓ General, physical, emotional, mental,
and total fatigue
↑ Vigor
Carr et al. (23) 1 Terminal angiosarcoma IV vitamin C
30 g daily
1 week
None EORTC QLQ-C30 ↓ Fatigue
↓ Pain
↓ Nausea/vomiting
↓ Insomnia
↓ Appetite loss
↑ Global health
↑ Physical, emotional,
cognitive, and social
functioning
MFSI ↓ General, physical, emotional, mental,
and total fatigue
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We carried out a case study of an 81-year-old male with inop-
erable pulmonary angiosarcoma (23). IV vitamin C (30 g/session)
was initiated and QOL (EORTC QLQ-C30) and fatigue (MFSI-SF)
questionnaires were administered before and after seven con-
secutive days of vitamin C administration. The QOL question-
naire showed a 37% decrease in fatigue and complete cessation
of pain, nausea/vomiting, and insomnia, as well as ameliorated
loss of appetite, following vitamin C administration (Table 1).
Improvements in physical, emotional, cognitive, and social func-
tioning were also observed, as well as an enhancement of overall
QOL. With respect to the multidimensional aspects of fatigue, a
decrease in physical, emotional, and mental fatigue, resulting in a
50% decrease in total fatigue, was observed following vitamin C
administration.
POTENTIAL MECHANISMS OF THE QUALITY OF LIFE ACTION
A number of studies have reported low-plasma levels of vita-
min C in cancer patients and in some instances this can amount
to severe depletion (29, 30). However, the vitamin C status of
cancer patients is not often taken into consideration, despite its
potential to support many biological functions. Vitamin C is well
known for its potent antioxidant properties, being able to readily
scavenge free radicals and reactive oxygen species, and is asso-
ciated with decreased markers of oxidative stress in vivo (31,
32). Oxidative stress is a major etiological factor in the devel-
opment and progression of cancer (33), and radiotherapy and
some chemotherapeutic agents also act through increased pro-
duction of free radicals. Oxidative stress is thought to contribute
to chemotherapy-related weakness and fatigue (34), thus, vitamin
C may be able to decrease fatigue through decreasing off-target
oxidant-mediated toxicity of adjuvant therapy (27, 28). There is
also strong evidence implicating inflammation in the sequelae of
cancer-related fatigue (25) and preliminary studies have shown
that high-dose IV vitamin C reduces biomarkers of inflammation,
such as C-reactive protein (CRP), tumor necrosis factor (TNF-α),
interferon-γ (IFN-γ), and the interleukins IL-1, IL2, IL-6, IL-8, in
cancer patients (35, 36).
Vitamin C acts as an in vivo cofactor for a family of enzymes
involved in the biosynthesis of collagen, carnitine, neurotrans-
mitters, and neuropeptide hormones, as well as those involved in
the regulation of epigenetic marks and transcription factors (5).
Some of these mechanisms may account for its observed effects
on QOL. Vitamin C is a cofactor for two enzymes involved in the
biosynthesis of carnitine, which is required for the transport of
fatty acids into mitochondria during the breakdown of lipids for
the generation of metabolic energy, i.e., ATP (37); this suggests a
plausible mechanism by which vitamin C could alleviate physical
fatigue. Parenteral vitamin C (1.5–15 g/session) has been shown
to readily and rapidly reduce pain in patients with shingles (38,
39) and although the mechanism of its analgesic action is uncer-
tain, it is likely to be through its neuromodulatory functions (40).
Vitamin C acts as a cofactor in the synthesis of the neurotrans-
mitters norepinephrine, dopamine, and serotonin (the latter two
via recycling the enzyme cofactor tetrahydrobiopterin) (41), and
in the synthesis of neuropeptide hormones, such as oxytocin (42),
which has known mood enhancing effects. To date, no cancer- or
chemotherapy-related QOL studies have investigated the effect of
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IV vitamin C on biomarkers of oxidative stress, inflammation, or
its cofactor activities.
CONSIDERATIONS FOR FUTURE STUDIES
A number of important issues need to be taken into consideration
with respect to design of future studies assessing the efficacy of
IV vitamin C on the QOL of cancer patients (Table 2). A major
drawback of the QOL studies carried out to date is that none have
included a placebo control. Thus, it is not possible to rule out a
placebo effect, particularly as this effect tends to be more preva-
lent with measures of subjective symptoms such as pain (43).
Therefore, it is critical that future QOL studies comprise an IV
placebo control, either as a parallel arm or as part of a cross-over
study design. Although additional phase I–II trials are currently
underway, which will assess level of fatigue, pain control, and QOL
with IV vitamin C treatment (2, 44), these do not appear to have
placebo controls. It is noteworthy that some studies indicate that
the dose of vitamin C required for QOL improvement (e.g., 7.5–
10 g/session) (6, 7) may be lower than those typically administered
by physicians as adjuvant treatment (e.g., 25–100 g/session) (1).
The optimum vitamin C dose for QOL improvement has not been
determined.
To date, variable intervals of IV vitamin C administration, from
daily to once weekly (typically twice weekly) have been used, and
the duration of a course of treatment has also varied greatly, from
1 week to 12 months. None of the QOL studies have determined
how long the effect of an individual IV vitamin C session lasts;
this would inform the number of sessions required per week to
obtain a sustained improvement in QOL. The pharmacokinetics
of IV vitamin C has been well characterized in phase I studies of
cancer patients (8, 45); plasma vitamin C levels reach a maximum
at the end of the infusion, the average duration of which is typi-
cally 1.5 h (1), then immediately begin to drop, with a half-life of
approximately 2 h (8, 45). Although IV vitamin C administration
does not appear to adversely interfere with the chemotherapeutic
agents tested to date [gemcitabine, erlotinib, paclitaxel, and carbo-
platin (27, 28, 46)], it has been suggested that an interval of five
half-lives be allowed either side of IV chemotherapy as a strategy
for avoiding potential drug interactions (47). Thus, based on its
2 h half-life, infusion of vitamin C on the day prior to chemother-
apy would avoid any interactions with chemotherapeutic agents
that have not yet been tested in combination with vitamin C.
Other important considerations include patient characteristics,
particularly their vitamin C status. Cancer patients exhibit low
circulating vitamin C levels (29, 30), despite comparable dietary
intakes to healthy controls (48), and also exhibit lower plasma
vitamin C status following IV administration (36). This is pos-
sibly due to enhanced metabolic turnover of the vitamin due
to increased cancer- or chemotherapy-associated oxidative stress
and/or inflammation. Although IV vitamin C pharmacokinetics
was measured in one of the studies, which assessed QOL, patient
status at study entrance or following supplementation was not
reported (8). Measurement of patient vitamin C status at screen-
ing would allow stratification and also facilitate subgroup analysis
Table 2 | Considerations for future quality of life (QOL) studies.
Considerations Comments
Placebo control No QOL studies have used a placebo control
Ideally, use an IV placebo control as a parallel arm or cross-over study design
IV vitamin C dose Different IV vitamin C doses have been used to date (e.g. 7.5–100 g/session)
Ideally, determine minimum dose required as may be significantly lower than doses typically administered as adjuvant
treatment (1)
IV vitamin C interval
and duration
Different intervals for IV vitamin C administration have been used (e.g. once weekly to daily) and different durations have been
utilized (e.g. 1 week to 12 months)
Ideally, determine duration of effect post-IV vitamin C to inform the number of sessions/week required to obtain a sustained
improvement in QOL
IV vitamin C and drug
interactions
Some IV vitamin C and chemotherapy combinations have been tested (27, 28, 46)
Ideally, bracket chemo-/radiotherapy to avoid potential interactions if specific combination has not yet been tested
Patient characteristics Some studies have combined± chemo-/radiotherapy (7, 9) and some studies have combined different tumor types (6, 8, 9)
Ideally, quantify QOL effect with or without adjuvant treatment, and analyze individual tumor types due to varying symptoms
Vitamin C status No QOL studies have reported patient vitamin C status at baseline or following IV vitamin C administration
Ideally, measure vitamin C status at screening to stratify participants or exclude from study, or at baseline to facilitate subgroup
analysis
QOL measures Some studies have used EORTC-QLQ-C30 (6, 8, 9) and MFSI (22, 23), while others have used intensity of typical complaints (7)
Ideally, use standardized measures to facilitate cross study comparisons
Mechanisms No QOL studies have investigated potential mechanisms of IV vitamin C action
Ideally, measure appropriate biomarkers of activity (e.g., biomarkers of oxidative stress, inflammation, and cofactor activities)
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or exclusion from the study if vitamin C status is already satu-
rating, i.e., likely abrogating any effect of intervention (49). Some
QOL studies have included participants who are undergoing adju-
vant treatment as well as those who are not (7, 9). Furthermore,
some QOL studies have included patients with cancer at differ-
ent sites (6, 8, 9). Both of these factors are likely to impact on
the type and/or degree of side-effects, which impact on QOL
and should be taken into consideration when planning future
studies.
CONCLUSION
Due to the debilitating nature of cancer- and chemotherapy-
related fatigue and other side-effects that impact on QOL, any ther-
apy that can alleviate these symptoms will significantly improve
the QOL of sufferers. A number of phase I clinical trials have
shown that high-dose IV vitamin is safe and well tolerated in
cancer patients, either as a monotherapy (8, 45) or in combina-
tion with other chemotherapeutic agents (28, 46). Although direct
anti-cancer effects of IV vitamin C have not yet been confirmed
by these small studies, there is consistent evidence that IV vitamin
C can improve cancer patient’s QOL (6–9) and decrease multiple
aspects of fatigue (22, 23). Patients with cancer-related fatigue are
often prescribed central nervous system stimulants, despite a lim-
ited evidence base, and the fact that these are often ineffective (50).
Thus, if future intervention studies indicate that IV vitamin C is
an effective anti-fatigue therapy, this will reduce the use of inef-
fective medications and their accompanying side-effects. Overall,
additional well-designed placebo-controlled studies investigating
the effects of IV vitamin C on QOL of cancer patients appear
warranted.
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